Issue brief |

DR-TB Drugs Under the Microscope, 6th Edition

Five urgent actions to improve DR-TB treatment

Drug resistance is a major public health crisis thwarting the effective treatment and care of people living with tuberculosis (TB) – the world’s leading infectious disease killer. But with the release of new curative medicines and patient-minded improvements of treatment guidelines, drug-resistant TB (DR-TB) no longer has to be a death sentence.

However, countries, policymakers and health care providers tasked with reaching and treating people living with DR-TB must take concrete actions to get lifesaving medicines to the people who need them most.

The 6th edition of DR-TB Drugs Under the Microscope examines the current landscape of DR-TB drug pricing and access policies and outlines five urgent actions for governments, policymakers and health care providers: adopt new treatment guidelines; lower the price of breakthrough drugs; surmount prohibitive patents and licensing policies; implement effective drug procurement practices; and support public health-driven research and development (R&D).

Additional publications in the DR-TB Drugs Under the Microscope report series are available here.

Learn more about MSF’s work to improve access to lifesaving TB treatment.

Read Under the Microscope